Equities research analysts at HC Wainwright assumed coverage on shares of Cesca Therapeutics (NASDAQ:KOOL) in a report issued on Wednesday, May 23rd, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $1.50 price target on the biotechnology company’s stock. HC Wainwright’s price target indicates a potential upside of 188.46% from the company’s previous close.
Separately, ValuEngine upgraded shares of Cesca Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd.
NASDAQ KOOL traded down $0.02 during trading hours on Wednesday, reaching $0.52. The company had a trading volume of 1,357,600 shares, compared to its average volume of 391,682. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.61 and a quick ratio of 0.79. The stock has a market capitalization of $10.75 million, a P/E ratio of -0.53 and a beta of -1.06. Cesca Therapeutics has a 1-year low of $0.42 and a 1-year high of $6.44.
Cesca Therapeutics (NASDAQ:KOOL) last issued its quarterly earnings results on Thursday, March 22nd. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter. The company had revenue of $2.94 million for the quarter. Cesca Therapeutics had a negative net margin of 56.21% and a negative return on equity of 20.31%. analysts anticipate that Cesca Therapeutics will post -0.55 EPS for the current year.
Cesca Therapeutics Company Profile
Cesca Therapeutics Inc develops, commercializes, and markets a range of automated technologies and products for cell-based therapeutics in the United States, China, rest of Asia, Europe, and internationally. The company develops automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products.
Receive News & Ratings for Cesca Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cesca Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.